Ralf W. Dittmann

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Psychiatry
• Major depressive disorder

Psychiatry, Internal medicine, Schizophrenia, Randomized controlled trial and Olanzapine are his primary areas of study. His research is interdisciplinary, bridging the disciplines of Tolerability and Psychiatry. His study in Internal medicine is interdisciplinary in nature, drawing from both Psychosocial, Endocrinology and Physiology.

His Schizophrenia research incorporates elements of Young adult, Observational study and Quality of life. In his study, Meta-analysis and Clinical trial is strongly linked to Attention deficit hyperactivity disorder, which falls under the umbrella field of Randomized controlled trial. The Olanzapine study combines topics in areas such as Brief Psychiatric Rating Scale and Atypical antipsychotic.

His most cited work include:

• Nonpharmacological Interventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled Trials of Dietary and Psychological Treatments (668 citations)
• Cognitive Training for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials (294 citations)
• Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. (286 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Psychiatry, Clinical psychology, Attention deficit hyperactivity disorder, Olanzapine and Atomoxetine. Gastroenterology is closely connected to Placebo in his research, which is encompassed under the umbrella topic of Psychiatry. His study looks at the relationship between Clinical psychology and fields such as Rating scale, as well as how they intersect with chemical problems.

His Attention deficit hyperactivity disorder research includes elements of Clinical trial, Psychometrics, Randomized controlled trial, Quality of life and Meta-analysis. His Olanzapine research integrates issues from Internal medicine, Clozapine and Atypical antipsychotic. His research in the fields of Atomoxetine hydrochloride overlaps with other disciplines such as In patient.

He most often published in these fields:

• Psychiatry (58.82%)
• Clinical psychology (29.41%)
• Attention deficit hyperactivity disorder (27.45%)

What were the highlights of his more recent work (between 2014-2021)?

• Clinical psychology (29.41%)
• Psychiatry (58.82%)
• Attention deficit hyperactivity disorder (27.45%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Clinical psychology, Psychiatry, Attention deficit hyperactivity disorder, Rating scale and Pediatrics. He has included themes like Randomized controlled trial and Autism, Autism spectrum disorder in his Clinical psychology study. His work on Child and adolescent psychiatry is typically connected to Pandemic as part of general Psychiatry study, connecting several disciplines of science.

His research in Attention deficit hyperactivity disorder intersects with topics in Quality of life and Discontinuation. Ralf W. Dittmann works mostly in the field of Pediatrics, limiting it down to topics relating to Adverse effect and, in certain cases, Methylphenidate, Meta-analysis and Mood. His research investigates the connection with Atomoxetine hydrochloride and areas like Placebo which intersect with concerns in Severity of illness.

Between 2014 and 2021, his most popular works were:

• Cognitive Training for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials (294 citations)
• Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. (127 citations)
• Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. (64 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Psychiatry
• Major depressive disorder

Ralf W. Dittmann focuses on Psychiatry, Attention deficit hyperactivity disorder, Clinical psychology, Randomized controlled trial and Child and adolescent psychiatry. His work deals with themes such as Observational study, Off-label use, Tolerability, Prospective cohort study and Medical prescription, which intersect with Psychiatry. Ralf W. Dittmann works mostly in the field of Attention deficit hyperactivity disorder, limiting it down to topics relating to Meta-analysis and, in certain cases, Sudden death, Adverse effect, Confidence interval, Atomoxetine hydrochloride and Comorbidity, as a part of the same area of interest.

His study in Clinical psychology is interdisciplinary in nature, drawing from both Intervention and Reliability. His Randomized controlled trial research includes themes of Neuropsychology, Behaviour therapy, Parent training, Impulsivity and Referral. His Child and adolescent psychiatry research is multidisciplinary, incorporating perspectives in Psychosocial and Anxiety.